The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study.
Genes (Basel)
; 11(2)2020 02 06.
Article
em En
| MEDLINE
| ID: mdl-32041307
ABSTRACT
The molecular heterogeneity of glioblastoma has been linked to differences in survival and treatment response, while the development of personalised treatments may be a novel way of combatting this disease. Here we show for the first time that low passage number cells derived from primary tumours are greater than an 86% match genetically to the tumour tissue. We used these cells to identify eight genes that could be used for the personalisation of glioblastoma treatment and discovered a number of personalised drug combinations that were significantly more effective at killing glioblastoma cells and reducing recurrence than the individual drugs as well as the control and non-personalised combinations. This pilot study demonstrates for the first time that whole exome sequencing has the potential be used to improve the treatment of glioblastoma patients by personalising treatment. This novel approach could potentially offer a new avenue for treatment for this terrible disease.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Regulação Neoplásica da Expressão Gênica
/
Glioblastoma
/
Polimorfismo de Nucleotídeo Único
/
Medicina de Precisão
/
Exoma
/
Antineoplásicos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Genes (Basel)
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Reino Unido